Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Common Equity (2016 - 2026)

Apyx Medical filings provide 16 years of Common Equity readings, the most recent being $14.5 million for Q4 2025.

  • On a quarterly basis, Common Equity rose 2.32% to $14.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $14.5 million, a 2.32% increase, with the full-year FY2025 number at $14.5 million, up 2.32% from a year prior.
  • Common Equity hit $14.5 million in Q4 2025 for Apyx Medical, up from $5.8 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $60.2 million in Q1 2021 to a low of $5.8 million in Q3 2025.
  • Median Common Equity over the past 5 years was $34.9 million (2023), compared with a mean of $31.8 million.
  • Biggest five-year swings in Common Equity: tumbled 66.66% in 2024 and later rose 2.32% in 2025.
  • Apyx Medical's Common Equity stood at $54.0 million in 2021, then plummeted by 30.02% to $37.8 million in 2022, then dropped by 28.76% to $26.9 million in 2023, then plummeted by 47.22% to $14.2 million in 2024, then grew by 2.32% to $14.5 million in 2025.
  • The last three reported values for Common Equity were $14.5 million (Q4 2025), $5.8 million (Q3 2025), and $7.5 million (Q2 2025) per Business Quant data.